NCT01229215View on ClinicalTrials.gov

A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy

PHASE2CompletedINTERVENTIONAL

Enrollment

143

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Geographic Atrophy

Interventions

DRUG

FCFD4514S

Repeating intravitreal injection

DRUG

sham

Repeating sham injection

Trial Locations (36)

10003

New York

11563

Lynbrook

14642

Rochester

19104

Philadelphia

19107

Philadelphia

21287

Baltimore

28210

Charlotte

29169

West Columbia

30909

Augusta

32503

Pensacola

33334

Fort Lauderdale

33410

Palm Beach Gardens

33426

Boynton Beach

33880

Winter Haven

37203

Nashville

42001

Paducah

44122

Beachwood

45242

Cincinnati

48145

Münster

53127

Bonn

53226

Milwaukee

55435

Edina

69120

Heidelberg

72076

Tübingen

75231

Dallas

78705

Austin

79106

Freiburg im Breisgau

79606

Abilene

85704

Tucson

90211

Beverly Hills

90503

Torrance

93103

Santa Barbara

94107

San Francisco

97210

Portland

02114

Boston

04103

Leipzig

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY